Penumbra’s Ruby XL coil could increase market share in peripheral embolisation coils

Penumbra’s Ruby XL system has recently received approval from the US Food and Drug Administration and consists of three coils: the Ruby XL, the POD XL, and the Packing Coil XL. This system is designed for vascular embolization procedures to block or close off blood vessels, with the Ruby XL used for large aneurysms, the POD XL for high-flow vessels, and the Packing Coil XL for vessels up to 70cm in length. Notably, all coils within the Ruby XL system can be delivered through a 0.035-inch diagnostic catheter, simplifying the process for physicians.

GlobalData, a prominent data and analytics company, speculates that the introduction of the Ruby XL system could significantly enhance Penumbra’s market share in the field of peripheral embolization coils. Currently, Penumbra holds a significant portion of the market share for these coils, as reflected in GlobalData’s US healthcare facility invoicing database. The versatility of the Ruby XL system allows for a broader range of aneurysm sizes to be addressed, potentially attracting more physicians to choose Penumbra’s coils for their procedures.

Moreover, the approval of the Ruby XL system has the potential to widen the gap between Penumbra and its competitors in the market. Physicians may opt for Ruby XL coils due to their effectiveness in managing large aneurysms, further solidifying Penumbra’s position in the market. Additionally, the Ruby XL system offers cost savings for consumers by providing more volume per coil compared to other available options. With its competitive price range of approximately $900 to $2,000, Penumbra is poised to maintain its advantage in the market with the introduction of these new coils.

As facilities begin to purchase the Ruby XL system in June 2025, Penumbra is anticipated to either maintain or increase its market lead in peripheral embolization coils. GlobalData will continue to track market trends closely to gauge the impact of these new coils on the industry. The potential cost benefits and efficacy of the Ruby XL system may lead to a shift in market dynamics, potentially favoring Penumbra over its competitors.

Overall, the Ruby XL system represents a significant advancement in the field of vascular embolization, offering physicians a versatile and cost-effective solution for addressing a wide range of vascular conditions. With its potential to capture a larger market share and deliver enhanced outcomes for patients, Penumbra’s Ruby XL system is poised to make a substantial impact in the healthcare industry.